Dactinomycin: CAS No: 50-76-0 No: 50-76-0 Dactinomycin (or actinomycin D) was the very first known antibiotic that helped fend off cancer. It’s now a standard chemotherapy medication being used to treat a variety of tumorous diseases. Doctors will typically reach for dactinomycin for sarcoma, ovarian cancer, and Wilm’s tumor. It can also be used with certain types of neoplasia and skin moles. The[…]
Dactinomycin: An Old Chemotherapy API with New Demand
Antibiotic Tags: antibioticcancer treatmentchemotherapy Jan 16, 2019
Carbapenems API’s for Antibiotic Resistance
Antibiotic, Drug Research & Development API Tags: antibioticCDCUnited States May 27, 2016
Biapenem CAS No: 120410-24-4 Doripenem CAS No: 148016-81-3 Ertapenem CAS No: 153832-46-3 Imipenem CAS No: 74431-23-5 Meropenem CAS No: 96036-03-2 Panipenem CAS No: 87726-17-8 A new publication is out called “May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations” and it highlights the antibiotic-resistant infections which are being seen for the 1st[…]
Amoxicillin Effective When Timed Optimally Before Surgery
Antibiotic, Drug Research & Development API, Patent Expiration 2020, TEVA API Tags: antibiotic Aug 18, 2014
Antibiotics, such as Amoxicillin, are extremely effectual when used appropriately prior to surgical procedures. The expiration of the potent antimicrobial drug Moxatag, also known as Amoxicillin, on October 13, 2020, paves the way for additional development of this generic powerhouse. Study results recently released in Infection Control and Hospital Epidemiology reveal that timing is[…]
Pyrazinamide is a Triple Threat to TB in HIV Patients
Anti-Retroviral / Anti-HIV, Antibacterial, Antibiotic, Drug Research & Development API Tags: HIV infectionHIV virus Aug 08, 2014
Midstage trial data of a Pyrazinamide cocktail to treat TB has offered encouraging news for patients with the HIV infection. Coined PaMZ, this drug trio includes Pyrazinamide and two antibacterial drugs, with results going into the Phase III trial looking promising. The antibacterial drugs are PA-824, which was initially developed by the Novartis and the[…]
Amikacin Glean Breakthrough Therapy Status
Antibacterial, Antibiotic, Drug Research & Development API, FDA Breakthrough Therapy Status, OTC and Compounding Product Tags: cystic fibrosis Jul 23, 2014
The end of June 2014 brought exciting news for Insmed’s liposomal Amikacin, known as the brand name Arikace, with a Breakthrough Status award from the FDA. Amikacin was specifically designated Breakthrough Status for treatment refractory nontuberculous mycobacterial lung disease in adult patients. As an inhaled antibiotic Amikacin is effectual for treating chronic nontuberculous mycobacterial lung[…]
FDA Approves Dalbavancin for the Treatment of Acute Skin Infections
Antibacterial, Antibiotic, Drug Research & Development API, FDA Approved 2014 Tags: antibiotic Jun 12, 2014
Exciting news was announced at the end of May 2014 from Durata Therapeutics with the FDA approval of Dalbavancin, their novel antibiotic treatment. Known as the brand name Dalvance, the FDA nod for Dalbavancin meets a current need for new, safe and efficacious antibiotics. Dalbavancin is officially approved to treat skin structure and bacterial skin infections[…]
Weak Sales and a Recall of Daptomycin Reported
Antibacterial, Antibiotic, Drug Research & Development API, Patent Expiration 2019 Tags: antibiotic May 08, 2014
Daptomycin, recognized as the brand name antibiotic Cubicin, has a patent expiration of September 24, 2019. Cubist Pharmaceutical markets Cubicin and they recently released a report revealing surprisingly weak sales. Initially Cubist reported strong sales of Daptomycin for the first quarter of 2013, with an overall rise in their revenues due to this potent antibiotic.[…]
Lead Product Candidate Delafloxacin Gains Funding
Antibacterial, Antibiotic, Drug Research & Development API Tags: antibioticMRSA Feb 24, 2014
On February 10, 2104 a substantial financial deal was announced by Melinta Therapeutics involving their projected blockbuster antibiotic Delafloxacin. A whopping 70 million dollar Series 3 equity financing deal was revealed, with various investors taking part, including Vatera Healthcare Partners. This extraordinary financing will be appropriated largely to advance the continued development, assessment and eventual[…]
Shortage of Tobramycin Affects Many
Antibiotic, Drug Research & Development API, FDA Drug Shortage, OTC and Compounding Product Tags: antibioticcystic fibrosis Sep 13, 2013
As an aminoglycoside antibiotic effective for treating a wide variety of infections, Tobramycin CAS# 32986-56-4 is an integral medication that affects a vast number of patients. Tobramycin is particularly effectual for treating Gram-negative infections and certain Pseudomonas. The recent shortage of this crucial antibiotic has been felt for patients who take Tobramycin, either as an[…]
Telavancin Gains Expanded-Use Approval by the FDA
Antibiotic Tags: antibioticEuropeMRSA Jul 16, 2013
In late June 2013 Telavancin, also known as the brand name antibiotic Vibativ, was approved by the FDA to treat bacterial pneumonia. Marketed by Theravance, Telavancin is an efficacious antibiotic treatment that has been previously approved in both the United States and Europe for bacterial and skin infections. This new approved indication for Telavancin is[…]
